📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-15 17:25
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
Bilcare Shareholders Reject Executive Appointments of Mohan Bhandari and Kavita Bhansali
Bilcare Ltd announced that shareholders failed to pass special resolutions at the 39th AGM on 26 September 2026 to appoint Mr. Mohan Bhandari and Ms. Kavita Bhansali as Executive Directors. Consequently, Mohan Bhandari will remain as Non-Executive Non-Independent Director & CEO, while Kavita Bhansali will continue as a Non-Executive Non-Independent Director. Promoter holding in the company stands at 30.01%, indicating significant institutional or public shareholder pushback against the board's August 2026 executive designations.
Confidence: HIGH
What changedShareholders rejected the executive directorships of Mohan Bhandari and Kavita Bhansali, altering their designations back to non-executive board roles.
Why it mattersDemonstrates shareholder resistance to promoter/board proposals, which could signal governance scrutiny and impact executive operational authority and remuneration.
AGM date: 26 September 2026Board meeting date: 13 August 2026Promoter holding: 30.01%
📅 Short termMay weigh on sentiment due to governance friction between minority shareholders and the board.
📈 Long termSignals stronger shareholder activism, requiring management to maintain better alignment with public shareholders on board governance and remuneration.
⚠ Risk flags
- Shareholder dissent on board appointments
- Potential leadership instability or compensation renegotiations
Key Highlights
Special resolutions proposed at the 39th AGM on 26 September 2026 were defeated due to lack of requisite majority
Mohan Bhandari reverts from Executive Director to Non-Executive Non-Independent Director & CEO
Kavita Bhansali continues only as a Non-Executive Non-Independent Director instead of Executive Director
Board's earlier approval from the 13 August 2026 meeting was effectively overridden by shareholders
👀 What to Watch
Monitor upcoming board disclosures regarding executive compensation, management leadership structure, and resolutions at subsequent shareholder meetings.
Bilcare AGM: Shareholders Defeat RPT with Caprihans and Executive Re-appointments
Bilcare Limited announced the voting results of its 39th AGM held on September 26, 2026. While ordinary resolutions adopting FY26 financials and director retirements by rotation were passed, three key special resolutions were defeated by shareholders. The rejected proposals include the re-appointment of Kavita Bhansali as Executive Director, appointment of Mohan Bhandari as Executive Director for 3 years, and material related-party transactions with Caprihans India Limited where 98.44% of non-promoter votes were cast against.
Confidence: HIGH
What changedShareholders rejected the executive directorships of Kavita Bhansali and Mohan Bhandari, as well as material related-party contracts with Caprihans India Limited.
Why it mattersThe rejection of executive leadership appointments creates governance ambiguity, and the inability to execute material related-party transactions with Caprihans India could disrupt planned commercial arrangements or supply-chain operations.
Votes against RPT resolution (Item 6): 98.44%Votes cast against RPT with Caprihans: 39,77,944Total shareholders on record date: 15962AGM date: 26 September 2026
📅 Short termHeightened scrutiny and uncertainty around top executive positions and supply-chain/trading activities tied to Caprihans India.
📈 Long termStrong public shareholder activism poses constraints on promoter-led governance and related-party agreements, necessitating structural governance realignments.
⚠ Risk flags
- Corporate governance uncertainty following defeated executive directorships
- Operational disruption from rejection of material related-party transactions
Key Highlights
Resolution 6 approving Material Related Party Transactions with Caprihans India Limited was defeated, with 98.44% (39,77,944 votes) of valid votes cast against.
Special resolutions (Items 3 and 5) appointing Ms. Kavita Bhansali and Mr. Mohan Harakchand Bhandari as Executive Directors were defeated.
Ordinary resolutions (Items 1, 2, and 4) including adoption of FY26 financial statements were passed with 64.53% overall votes in favour.
Total valid votes cast for the general resolutions stood at 1,12,10,296 across 15,962 total shareholders on the record date.
👀 What to Watch
Track subsequent board announcements regarding executive management leadership and operational adjustments following the rejection of material related-party transactions with Caprihans India.
Bilcare Q1 Standalone Profit Rs 1.04 Cr; US Subsidiary with Nil Revenue to be Wound Up
Bilcare Ltd reported a standalone net profit of Rs 1.04 Cr for Q1 FY27, down from Rs 3.59 Cr in the year-ago period. The Board approved the voluntary winding up of its US-based wholly owned subsidiary, Bilcare INC, which reported zero turnover in FY26. Significant management changes were announced, including the appointment of Mr. Mohan Bhandari as Executive Director and a new Company Secretary. The company continues to navigate an ongoing SFIO investigation and maintains land assets held for sale valued at Rs 64.07 Cr.
Confidence: HIGH
What changedThe company is streamlining its global structure by closing an inactive US subsidiary and has refreshed its senior management and secretarial leadership.
Why it mattersThe winding up of a non-operational subsidiary reduces administrative overhead, while the warrant conversion provides a necessary liquidity cushion for a company with a high debt-to-equity ratio of 3.15.
Q1 Standalone Revenue: Rs 1.94 CrQ1 Standalone Net Profit: Rs 1.04 CrAsset Held for Sale (Land): Rs 64.07 CrWarrant Conversion Payment: Rs 25.58 CrUS Subsidiary Turnover (FY26): NIL
📅 Short termThe market is likely to react neutrally as the standalone financial contribution is minimal compared to consolidated operations, and the subsidiary closure involves a non-earning unit.
📈 Long termThe structural overhang of high debt (Rs 620 Cr) and the SFIO investigation continue to challenge the 'going concern' status despite strategic management changes.
⚠ Risk flags
- Ongoing SFIO investigation (since June 2020) with unascertainable financial impact
- High Debt-to-Equity ratio of 3.15
- Auditor concerns regarding 'going concern' assumptions
Key Highlights
Standalone Total Income for Q1 FY27 stood at Rs 6.30 Cr compared to Rs 8.79 Cr in Q1 FY26.
Net Profit of Rs 1.04 Cr recorded after accounting for an exceptional loss of Rs 1.74 Cr due to forfeited warrants.
Voluntary winding up of Bilcare INC (USA) initiated; the unit had NIL turnover and net worth contribution in FY26.
Company received Rs 25.58 Cr during the quarter towards the 75% balance payment for 17,05,000 warrants.
Assets held for sale, comprising land parcels, are carried at a book value of Rs 64.07 Cr as of June 30, 2026.
👀 What to Watch
Investors should monitor the monetization of the Rs 64.07 Cr land assets and the outcome of the ongoing SFIO investigation, which remains a primary risk factor.
Bilcare Q1 Standalone Profit Drops to ₹1.04 Cr; USA Subsidiary to be Wound Up
Bilcare Ltd reported a standalone net profit of ₹1.04 Cr for Q1 FY27, a 71% decline from ₹3.59 Cr in the year-ago period. The company is streamlining its structure by voluntarily winding up its US subsidiary, Bilcare INC, which generated zero revenue in FY26. Management changes include the appointment of Mr. Mohan Bhandari as Executive Director and a new Company Secretary, Mr. Mayur Dave, effective September 2026. The company remains under SFIO investigation, and standalone operations remain small relative to its consolidated TTM revenue of ₹734 Cr.
Confidence: HIGH
What changedThe company has appointed a new Executive Director and Company Secretary, while initiating the closure of its non-operational US subsidiary.
Why it mattersThe standalone results show declining profitability in the holding entity, while the subsidiary closure is a routine administrative cleanup of a non-performing unit.
Standalone Q1 Net Profit: ₹1.04 CrYoY Profit Growth: -71.03%IEPF Transfer Amount: ₹2.93 CrDebt-to-Equity Ratio: 3.15Warrants Forfeited: 3,15,000 units
📅 Short termThe stock may see neutral to slightly negative sentiment due to the drop in standalone profits and the ongoing SFIO investigation note.
📈 Long termThe company's long-term viability depends on resolving its high debt levels and the outcome of regulatory investigations, despite its niche in pharma packaging.
⚠ Risk flags
- Ongoing SFIO investigation (since June 2020)
- High Debt-to-Equity ratio of 3.15
- History of consolidated net losses (₹-31 Cr TTM)
Key Highlights
Standalone net profit for Q1 FY27 fell to ₹1.04 Cr from ₹3.59 Cr in Q1 FY26.
Standalone revenue from operations stood at ₹1.94 Cr, a slight decrease from ₹2.07 Cr YoY.
Voluntary winding up of Bilcare INC (USA) approved; subsidiary had ₹0 revenue in FY26.
Transferred ₹2.93 Cr to the Investor Education Protection Fund (IEPF) following an NCLT order.
Forfeited 3,15,000 share warrants as the conversion option was not exercised by the holders.
👀 What to Watch
Investors should focus on consolidated results rather than standalone figures, as the latter represents less than 1% of TTM revenue. Monitor the outcome of the ongoing SFIO investigation and the company's high debt-to-equity ratio of 3.15.
Bilcare Q1 Standalone Profit ₹1.04 Cr; Appoints Mohan Bhandari as ED; Winds up US Subsidiary
Bilcare reported a standalone net profit of ₹1.04 Cr for Q1 FY27, a decline from ₹3.59 Cr in the year-ago period, on a marginal revenue of ₹1.94 Cr. The board approved the appointment of Mr. Mohan Bhandari as Executive Director and the voluntary winding up of its inactive US subsidiary, Bilcare INC. Additionally, the company complied with an NCLT order by transferring ₹2.93 Cr to the Investor Education Protection Fund (IEPF) and forfeited 3,15,000 unexercised warrants.
Confidence: HIGH
What changedThe company has refreshed its board with the appointment of Mohan Bhandari as ED, initiated the closure of an inactive US subsidiary, and completed a mandatory transfer of funds to the IEPF.
Why it mattersThese actions represent corporate housekeeping and regulatory compliance. The standalone results are financially immaterial to the overall group scale but reflect ongoing administrative and legal obligations.
Q1 Standalone Revenue: ₹1.94 CrQ1 Standalone PAT: ₹1.04 CrIEPF Transfer Amount: ₹2.93 CrWarrants Forfeited: 3,15,000 unitsUS Subsidiary Turnover (FY26): ₹0
📅 Short termThe market is likely to react neutrally as the standalone earnings are small and the management changes are largely procedural.
📈 Long termThe structural cleanup of inactive subsidiaries is positive, but the company faces long-term challenges including high debt and an ongoing SFIO investigation.
⚠ Risk flags
- Ongoing SFIO investigation (since June 2020) with unascertainable financial impact
- High Debt/Equity ratio of 3.15
- Auditor note on 'going concern' uncertainties
Key Highlights
Standalone revenue for Q1 FY27 was ₹1.94 Cr, representing less than 1% of the group's TTM consolidated revenue of ₹734 Cr.
Net profit for the quarter stood at ₹1.04 Cr, down 71% from ₹3.59 Cr in Q1 FY26.
Voluntary winding up of Bilcare INC (USA) initiated; the subsidiary had ₹0 turnover in FY26.
Transferred ₹2.93 Cr to the Investor Education Protection Fund (IEPF) on July 10, 2026, following an NCLT order.
Forfeited 3,15,000 share warrants as the conversion option was not exercised by the holders.
👀 What to Watch
Investors should focus on the consolidated financial results rather than standalone figures to assess the core business performance. Monitor the progress of the ongoing SFIO investigation and the company's ability to manage its high debt-to-equity ratio of 3.15.
Bilcare Q1 Net Profit Falls to ₹1.04 Cr; Appoints Mohan Bhandari as ED & Winds Up US Subsidiary
Bilcare Ltd reported a standalone net profit of ₹1.04 cr for Q1 FY27, a 71% decline from ₹3.59 cr in the year-ago period. The company announced the appointment of Mohan Bhandari as Executive Director and the voluntary winding up of its US subsidiary, Bilcare INC, which had zero turnover in FY26. Standalone revenue remains minimal at ₹1.94 cr, while the company continues to navigate an ongoing SFIO investigation and high debt levels. Additionally, 3,15,000 share warrants were forfeited during the quarter as the conversion option was not exercised.
Confidence: HIGH
What changedThe company reshuffled its senior management with a new Executive Director and Company Secretary, while initiating the closure of a non-performing US subsidiary.
Why it mattersThe management changes and subsidiary cleanup are part of a strategic plan to focus on core segments, but the company remains under significant regulatory and financial stress, including a 'going concern' uncertainty noted by auditors.
Q1 Standalone Net Profit: ₹1.04 crQ1 Standalone Revenue: ₹1.94 crAsset Held for Sale: ₹64.07 crDebt-to-Equity Ratio: 3.15IEPF Transfer (July 2026): ₹2.93 cr
📅 Short termThe stock may face pressure due to the sharp YoY decline in standalone profits and the uncertainty surrounding the SFIO investigation.
📈 Long termStructural recovery depends on the successful execution of the 'value-added business' strategy and resolving significant pending litigations and debt obligations.
⚠ Risk flags
- Ongoing SFIO investigation (since June 2020)
- High Debt-to-Equity ratio of 3.15
- Going concern uncertainties cited by auditors
- Significant pending tax and transfer pricing litigations
Key Highlights
Standalone Net Profit decreased to ₹1.04 cr in Q1 FY27 from ₹3.59 cr in Q1 FY26.
Revenue from operations for the quarter stood at ₹1.94 cr, representing a small fraction of the ₹734 cr TTM consolidated revenue.
Voluntary winding up of wholly-owned US subsidiary Bilcare INC, which contributed ₹0 turnover in FY26.
Forfeiture of 3,15,000 share warrants during the quarter ended June 2026.
Asset Held for Sale (land parcels) continues to be carried at a book value of ₹64.07 cr.
👀 What to Watch
Investors should monitor the outcome of the ongoing SFIO investigation and the company's progress in monetizing its ₹64.07 cr land assets to address its high debt-to-equity ratio of 3.15.
Bilcare Q1 Standalone PAT at ₹1.04 Cr; USA Subsidiary Winding Up & Management Changes
Bilcare Ltd reported a standalone net profit of ₹1.04 Cr for Q1 FY27, a 71% decline from ₹3.59 Cr in the same quarter last year. Total standalone income fell to ₹6.30 Cr from ₹8.79 Cr YoY, while the company recorded an exceptional loss of ₹1.74 Cr due to the forfeiture of 3,15,000 lapsed share warrants. The board approved the voluntary winding up of its non-material US subsidiary, Bilcare INC, which had zero turnover in FY26. Additionally, the company underwent a management reshuffle with the appointment of a new Executive Director and Company Secretary.
Confidence: HIGH
What changedBilcare has reported a sharp drop in standalone quarterly profitability, initiated the closure of its non-operational US subsidiary, and appointed Mohan Bhandari as Executive Director.
Why it mattersThe standalone results show declining margins, and the ongoing SFIO investigation creates regulatory uncertainty. The winding up of the US subsidiary indicates a focus on streamlining non-performing global units.
Standalone Net Profit (Q1): ₹1.04 CrStandalone Total Income (Q1): ₹6.30 CrAsset Held for Sale (Land): ₹64.07 CrIEPF Transfer Amount: ₹2.93 CrExceptional Item (Warrant Forfeiture): ₹1.74 Cr
📅 Short termThe stock may face pressure due to the 71% YoY decline in standalone profit and the uncertainty surrounding the SFIO investigation.
📈 Long termStructural recovery depends on the resolution of high debt (₹620 Cr) and the successful execution of the 'going concern' strategy mentioned in the notes.
⚠ Risk flags
- Ongoing SFIO investigation (since June 2020) with unascertainable financial impact
- High Debt-to-Equity ratio of 3.15
- Going concern uncertainties noted by management/auditors
Key Highlights
Standalone Net Profit fell to ₹1.04 Cr in Q1 FY27 compared to ₹3.59 Cr in Q1 FY26.
Total Standalone Income declined 28% YoY to ₹6.30 Cr from ₹8.79 Cr.
Exceptional loss of ₹1.74 Cr recognized following the lapse and forfeiture of 3,15,000 share warrants.
Transferred ₹2.93 Cr to the Investor Education Protection Fund (IEPF) on July 10, 2026, per NCLT orders.
Voluntary winding up initiated for Bilcare INC (USA), a wholly-owned subsidiary with NIL turnover in FY26.
👀 What to Watch
Investors should monitor the outcome of the ongoing SFIO investigation and the company's ability to monetize ₹64.07 Cr in assets held for sale to improve liquidity. The high debt-to-equity ratio of 3.15 remains a key structural risk to track in upcoming consolidated results.
Bilcare Q1 Standalone Net Profit at ₹1.04 Cr; US Subsidiary to be Wound Up
Bilcare reported a standalone net profit of ₹1.04 cr for Q1 FY27, down from ₹3.59 cr in the year-ago period, on a total income of ₹6.30 cr. The company is initiating the voluntary winding up of its US-based wholly-owned subsidiary, Bilcare INC, which reported zero turnover in FY26. Management changes include the appointment of Mr. Mohan Bhandari as Executive Director and a transition in the Company Secretary role. Financial health remains pressured by high debt (D/E 3.15) and an ongoing SFIO investigation.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, appointed a new Executive Director, and decided to close its non-operational US subsidiary.
Why it mattersThe standalone results represent only a small fraction of the group's ₹734 cr TTM revenue, but the winding up of the US unit and the warrant forfeiture reflect ongoing corporate restructuring and capital changes.
Q1 Standalone Revenue: ₹1.94 crQ1 Standalone Net Profit: ₹1.04 crAsset Held for Sale vs Net Worth: ~32.5%IEPF Transfer Amount: ₹2.93 crWarrants Forfeited: 3,15,000 units
📅 Short termThe stock may see limited movement as standalone results are small relative to consolidated operations, though the US subsidiary closure simplifies the structure.
📈 Long termThe company faces structural challenges including high debt-to-equity (3.15) and 'going concern' uncertainties noted in previous filings.
⚠ Risk flags
- Ongoing SFIO investigation (since June 2020) with unascertainable financial impact
- High Debt-to-Equity ratio of 3.15
- Contingent liability of ₹18.55 cr regarding CSIR loan penal interest
Key Highlights
Standalone Total Income decreased to ₹6.30 cr in Q1 FY27 from ₹8.79 cr in Q1 FY26.
Net Profit for the quarter stood at ₹1.04 cr, a 71% decline compared to ₹3.59 cr YoY.
Forfeiture of 3,15,000 share warrants occurred as the conversion option was not exercised.
Transferred ₹2.93 cr to the Investor Education Protection Fund (IEPF) on July 10, 2026, per NCLT orders.
Land parcels valued at ₹64.07 cr continue to be classified as 'Assets Held for Sale'.
👀 What to Watch
Investors should monitor the outcome of the ongoing SFIO investigation and the potential liquidity boost from the sale of land parcels worth ₹64.07 cr.
